76 results about "Adrenal tissue" patented technology

An implantable medical device is provided for the treatment of a variety of disorders. The implantable medical device can be a neurostimulator having a stimulation lead and electrode(s) configured to be implanted on or near neural tissue in communication with the adrenal gland. Application of an electrical waveform to the neural tissue can cause the adrenal gland to release catecholamines to treat hypoglycemia. In other embodiments, chemical, magnetic, optical, or mechanical neuromodulation can be used.

The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder, bones, brain, breast, cervix, colon, colorectum, esophagus, gastrointestinal tract, heart, kidney, liver, large intestine, lungs, mouth, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, skin, small intestine, spleen, stomach, thymus, thyroid, testicles, urinary tract, uterus, vagina, and so forth.

Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches). The devices and methods may also be used to treat rhinitis, sinusitis, or rhinosinusitis, irrespective of whether those disorders are co-morbid with a headache. They may also be used to treat other disorders that may be co-morbid with migraine or cluster headaches, such as anxiety disorders. In preferred embodiments of the disclosed methods, one or both of the patient's vagus nerves are stimulated non-invasively. In other embodiments, parts of the sympathetic nervous system and/or the adrenal glands are stimulated.

The invention discloses a Chinese herbal medicinal composition for treating lung cancer. Each dose of the composition at least comprises rehmannia, astragalus, Chinese angelica, ginseng, hoptoad, Indian iphigenia bulb, black nightshade herb, slug and barbated skullcup herb. The materials are added and reduced according to different stages of the lung cancer and different metastases of the lung cancer, and the composition can be prepared in different weight ratios into any formulation in pharmaceuticals . The composition is used for treating early stage of lung cancer, later stage of lung cancer, brain metastasis of the lung cancer, bilateral lung metastasis, bone metastasis, liver metastasis, adrenal gland metastasis and the like. Hundreds of cases of clinical practices prove that the Chinese herbal medicinal composition has remarkable curative effect on the lung cancer, and has longer surviving time than the third generation chemo-therapy medicament.

The invention provides a preparation method of a brain-soothing hypertension pill. The brain-soothing hypertension pill is prepared by using 100g of baical skullcap roots, 60g of common selfheal fruit-spike, 60g of sophora flower bud, 60g of forged lodestone, 60g of twotooth achyranthes roots, 100g of Chinese angelica, 40g of rehmannia, 40g of danshen roots, 20g of sanguisuga, 60g of uncaria rhynchophylla, 100g of semen cassia, 20g of lumbricus and 40g of nacre as bulk drugs and adopting supercritical extraction and microwave-assisted extraction modes. By adopting the method, the content of baicalin is greatly improved; and the invention also provides application of the brain-soothing hypertension pill in preparation of drugs for inhibiting cell proliferation of rat adrenal pheochromocytoma PC-12.

A Chinese medicine in the form of dispersing tablet or oral liquid for improving immunity and constitution, protecting the function of bone marrow and adrenal cortex, and promoting the function recovery after radiotherapy and chemicotherapy is prepared from lucid ligustrum fruit and astragalus root.

The invention relates to a medicine component used for curing or lightening melancholia or a neurodegeneration disease. The medicine component used for curing or lightening the melancholia or the neurodegeneration disease comprises at least one type of Chinese herbal medicine which is chosen from a group which is composed of ortex phellodendri, radix scutellariae, rhizoma chuanxiong,astragalus, eucommia, Saposhnikovia divaricata and rhizoma corydalis, and the Chinese herbal medicine in the group is capable of promoting rebirth of a neural stem cell and adjusting hypothalamus-infracerebral gland-adrenal gland axis or antiapoptosis. The invention further provides a purpose used for manufacturing the medicine component used for curing or lightening the melancholia or the neurodegeneration disease. The purpose used for manufacturing the medicine component used for curing or lightening melancholia or the neurodegeneration disease comprises at least one type of the Chinese herbal medicine which is capable of promoting rebirth of the neural stem cell and adjusting the hypothalamus-infracerebral gland-adrenal gland axis or the antiapoptosis.

The invention provides a fleece-flower root life-prolonging tablet for treating baldness according to the theory that the baldness is treated in need of treating liver and kidney firstly. The formula of the fleece-flower root life-prolonging tablet is as follows according to the weight ratio: 300-400 parts of polygonum multiflorum, 18-22 parts of rehmannia, 14-20 parts of semen sesami nigrum, 30-50 parts of the root of bidentate achyranthes, 150-200 parts of mulberry, 30-50 parts of fructus ligustri lucidi, 200-250 parts of eclipta, 30-50 parts of folium mori, 70-90 parts of semen cuscutae, 230-280 parts of fructus rosae laevigatae, 30-50 parts of fructus psoraleae, 60-100 parts of phlomis bracteosa royle and 15-25 parts of honeysuckle. The modern pharmacology research shows that the fleece-flower root life-prolonging tablet has the functions of resisting free radicals, preventing lipid peroxidation, reducing activity of monoamine oxidase, enhancing the function of adrenal gland and the like; in addition, the fleece-flower root life-prolonging tablet can lessen the formation of experimental atheromatous plaques and lipid deposition, so as to exert the functions of reducing blood fat and resisting atherosclerosis.

The present invention relates to methods for (1) reducing the number and severity of acne lesions on the skin of a mammal; (2) ameliorating the inflammation of acne lesions on the skin of a mammal; (3) improving the skin tone of a mammal, (4) treating skin disorders; (5) treating stress related skin diseases; (6) reducing stress and improving the emotional well being of an acne sufferer; (7) reducing sebaceous gland output; and (8) increasing compliance of the administration of anti-acne products. The method comprises the administration of a sensory regimen in an amount effective to downregulate the activity of the hypothalamus-pituitary-adrenal (HPA) axis in combination with the administration of an anti-acne composition.

The invention discloses an external compound abafenjing drug composition, which comprises the following parts: 0.01-20% abafenjing, 0.005-1% adrenal cortex hormone, medical auxiliary material and antibacterial material. The invention reduces the injury of infected skin, which can treat vaginal candidiasis and vulvopathy.

The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental language disorders, developmental speech disorders, developmental delay, Alzheimer's disease, diabetes, heart disease, obesity, ALS, nephritic syndrome, renal failure, asthma, systemic lupus, autoimmune thyroiditis, rheumatoid arthritis, arthritis, vasculitis, myelitis, glomerulonephritis, optic neuritis, infantile cerebral palsy, epilepsy, migraine, toxic encephalopathy, polyneuropathy, cerebral degenerations, anterior horn cell disease, spinocerebellar disease, extrapyramidal disease, and myopathy, and other related disorders. The invention of a method of screening, studying and treating of these disorders by utilizing the interaction of mercurial with the steroidgenesis pathway and its control by the hypothalamus-pituitary-adrenal axis is described.

The invention belongs to the field of biomedicine, relating to a method for establishing a chronic obstructive pulmonary disease superposition asthma model. By adopting a combined method of Drip endotoxin and smoke in trachea and egg albumin sensitization inspiration, the invention has reliable evaluation on aspects of lung tissue pathology, bronchial reactivity, serum cytokine, hypothalamus-hypophysis-adrenal axis and the like. The result of comparison with the pure chronic obstructive pulmonary disease or asthma model shows that the chronic obstructive pulmonary disease superposition asthma model has the characteristic change of the chronic obstructive pulmonary disease or asthma and weakens or intensifies the charateristic pathologic physiological changes. The invention has the advantages of simple preparation and good reliability and repetitiveness, and meets the disease pathologic physiological characteristics of the chronic obstructive pulmonary disease merger asthma, and can be used for the research of pathogenic mechanisms, prevention and treatment, and the like of the chronic obstructive pulmonary disease merger asthma.

The invention relates to an application of Morphine in preparing medicaments for treating the Parkinson disease, in particular to a new medical application of Morphine, belonging to the technical field of medicines. Through a thiazolyl blue (MTT) method, the Morphine is found to be capable of promoting the growth of adrenal gland chromaffin tumor cells (PC12 cells) of rats. The Morphine has the activity of promoting the proliferation of nerve cells and can inhibit nerve cell injuries caused by a Parkinson toxic substance MPP+(1-Methyl-4-Phenylpyridiniumion). Proved by a protein immunoblotting method, the Morphine can induce the expression level of thioredoxin in the PC12 cells, thus the Morphine for protecting the nerve cells from injuries of MPP+ toxicity is related to the induction of the expression of the thioredoxin.

The present invention discloses solid phase synthesis process of adrenal medullarin (27-52). The synthesis process includes the first solid phase Fmoc polypeptide synthesis to graft protective amino acid Fmoc-Ala-OH onto resin, connecting the rest protective amino acids successively, cutting down the synthesized coarse peptide with peptide cutting reagent, and final separating and purifying to obtain the adrenal medullarin (27-52) as the target peptide. The present invention has mild reaction condition, high reaction rate, less side reactions, easy purification, high yield, no corrosion to the equipment and no environmental pollution.

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

The invention relates to a new medical use of KCl, application of the KCl as nerve cell growth promoter, PC12 cell growth promoter, antioxidant stress damage agent and PC12 cell parkinson toxic-free damage agent, and application of the KCl in preparing medicament for treating Parkinson disease. By adopting a methyl thazolyl tetrazolium (MTT) method, the KCl is found to have the effects of promoting the growth of adrenal gland chromaffin tumor cell (PC12 cell), promoting the activity of the nerve cell multiplication and inhibiting the damage of the nerve cell caused by the Parkinson toxic substance MPP+(1-Methy1-4-Phenylpyridinium ion). The western blotting method shows that the KCl can induce the expression level of thioredoxin in the PC12 cell. Therefore, the KCl for protecting the nerve cells against the toxicity MPP+ is related to the expression of the thioredoxin.